Integrin receptor antagonists

Details Integrin receptor antagonists Integrin receptor antagonists

1997-01-14

1999-09-14

Gerstl, Robert

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 19, 544360, 544393, 546122, 546194, 5462734, 5462774, 546300, 546309, 546331, C07K 5023, A61K 3805, A61K 3806

Patent

active

059523069

ABSTRACT:
Fibrinogen receptor antagonists having the formula ##STR1## for example ##STR2## which are useful for inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.

REFERENCES:
patent: 3553227 (1971-01-01), Westland
patent: 4122255 (1978-10-01), Krapcho et al.
patent: 4250183 (1981-02-01), Krastinat
patent: 4684722 (1987-08-01), Sundeen
patent: 5227490 (1993-07-01), Hartman et al.
patent: 5264420 (1993-11-01), Duggan et al.
patent: 5281585 (1994-01-01), Duggan et al.
patent: 5292756 (1994-03-01), Duggan et al.
patent: 5294616 (1994-03-01), Duggan et al.
patent: 5321034 (1994-06-01), Duggan et al.
patent: 5358956 (1994-10-01), Hartman et al.

Affiliated with

Also associated with

Rating

Integrin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Integrin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1509780